Dashboard PDUFA PDUFA History Dilution Watch Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Track ALZN with free AI briefings, catalyst countdowns, and dilution alerts.

ALZN · Alzamend Neuro, Inc.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$7.6M Cash on Hand

11.6mo Cash Runway

Follow ALZN by email Get an email when ALZN pushes back a promised milestone, files for a stock offering or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about ALZN, unsubscribe in one click. Privacy

🧪 Trial & FDA Catalysts

Dec 2026 · Phase 1/2 · Recruiting · A Study to Investigate Lithium Brain/Plasma Pharmacokinetics and Safety of an AL001 Oral C
Registry primary completion date, not a results date
Mar 2028 · Phase 1/2 · Active Trial · Study in Subjects With Mild-to-Moderate Alzheimer's Dementia
Registry primary completion date, not a results date

📊 Drug Pipeline

Drug	Indication	Most advanced trial	Status
Lithium Salicylate	Bipolar I Disorder	Phase 1/2 · NCT07540338	Recruiting
ALZN002 (autologous DCs pulsed with E22W	Alzheimer Disease	Phase 1/2 · NCT05834296	Active not recruiting

Also used in these trials (approved or third-party drugs, not ALZN's own candidates): Lithium Carbonate.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

ALZN holds $7.6M in cash and short-term investments (as of Jul 31, 2026) and burns about $2M/quarter from operations, an estimated runway of 11.6 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 55 · Elevated

Cash runway 12 months +30
ATM program on file since Mar 2026 +15
Share count +54% in a year +20
Raised after last reported balance sheet (Aug 2026) -10

Recent financing filings on SEC EDGAR:

Aug 3, 2026 · Private placement (8-K Item 3.02) · 8-K
Mar 6, 2026 · ATM program, up to $3M · 424B5
Oct 9, 2025 · Private placement (8-K Item 3.02) · 8-K
Sep 25, 2025 · Private placement (8-K Item 3.02) · 8-K
Aug 1, 2025 · Private placement (8-K Item 3.02) · 8-K
Feb 28, 2025 · Private placement (8-K Item 3.02) · 8-K

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when ALZN files for a raise →

👥 Who Owns ALZN

Insiders 2.8% Institutions (12 holders) 56.4% Public and other holders 40.8%

Holder	Type	Shares	% of shares	As of
Milton C Iii Ault Director · +131,822 options	Insider	127,777	2.65%	2026-08-26
David J Katzoff Chief Financial Officer · +300,000 options	Insider	5,540	0.11%	2025-03-21
Lynne Fahey McGrath Director	Insider	25	0.00%	2025-10-23

Share count 4,825,723 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full ALZN picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for ALZN and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z